The Quiet Strength of Merck & Co. : Beyond Keytruda's Shadow In recent years, pharmaceutical companies have faced intense scrutiny over their pricing strategies and regulatory hurdles. Amidst this backdrop, Merck & Co.
, Inc. has been quietly building a stronger future beyond its iconic cancer drug, Keytruda.
The company's performance in the market has caught the attention of investment advisory firm Auxier Asset Management, which highlighted Merck & Co. 's growth potential in its second quarter 2026 investor letter.